(Reuters) -Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for more than $70 per share, Bloomberg News reported, citing a person familiar with the matter who said an announcement ...
Hosted on MSN
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity. 10 stocks we like better ...
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical ...
An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...
This is read by an automated voice. Please report any issues or inconsistencies here. San Diego-based Avidity Biosciences Inc. agreed to be acquired by Novartis AG in a deal valued at $12 billion.
SAN DIEGO, Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated ...
Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular ...
ALLISON GATLIN Thu, March 30, 2023 at 8:16 PM UTC 2 min read Avidity Bio Crashes 17% After 'Rarer Than Rare' Event Sidelines Key Study ...
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Avidity Biosciences (RNA – Research Report) yesterday and set a price target of $50.00. Yanan Zhu’s Buy rating for Avidity Biosciences is ...
In a deal that could bring Avidity Biosciences Inc. $2.3 billion if all milestones are met, Bristol Myers Squibb Co. gained global rights to Avidity’s antibody oligonucleotide conjugates platform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results